Generic Prostitution Policy

940 Words4 Pages

Generic substitution (GS) policy has been considered for future implementation (Ministry of Health Malaysia, 2009), which is supported by community pharmacists although the majority prefer a voluntary GS to compulsory GS. Most of the patients accept the offer of GS by community pharmacists and lead to further improvement of the feasibility of policy. Nonetheless, consumers need to be educated about generic medicnes to gain sufficient knowledge and eliminate negative perceptions in order to improve acceptance and utilisation of generic. Generic medicines passing bioequivalence tests are currently listed on the “generic product list for bioequivalence studies”, which is disseminated and published online for easy access to healthcare professionals …show more content…

Meanwhile, vitamins manufactured in Malaysia are being exported to Singapore, Vietnam, Brunei, Hong Kong, Taiwan, India, Japan, Germany and certain countries in Africa and Central America. The total export value of drugs from Malaysia stood at US$131 million (RM399 million) in 2004 and has been growing at a CAGR of 5.4% from 2006 till 2013, according to Frost & Sullivan. Malaysian generic pharmaceutical market was valued at RM 390 million (2001). Annual growth rate of 10 percent and a CAGR(2001 to 2007) of 12.5%. The key factor for generic drug players to produce generic versions of the drugs and increase market share is the ability of our local generic manufacturers to take advantage by preparing new products in their production pipeline, appropriate manufacturing facilities and bioequivalent to the proprietary …show more content…

Malaysia is the pioneer and global leader in the manufacturing and certification of halal medicines for export to other Muslim countries. The Chemical Company of Malaysia (CCM) was the first pharmaceutical firm to be awarded a halal certification, mainly for OTC products in January 2013. Recently in 2013, Indian drug maker Ranbaxy announced it will invest USD35 million into a second new facility to manufacture generic drugs in Malaysia. Besides that, Malaysia also export to the ASEAN markets such as Middle East, Europe, Sri Lanka, China and other countries. Current trends in generic drug business which are the eight significant acquitions in 2006 for example Dr Reddy’s Laboratories outbid Teva (world largest generics company) to acquire Betapharm (Germany 4th largest), Ranbaxy to acquire Terapia (Romania’s largest generics company),Hospira to acquire Mayne Pharma, Barr Pharmaceutical to acquire Pliva, Mylan Labs to acquire Matrix, Stada Arzneimittel to acquire Hemopharm, Actavis to acquire Sindan. Spiraling healthcare cost and the healthcare expenditure = 3.1 – 5.0% of the GDP in year 2006 (Medical Cost Reference Guide, 2006). Government reduces expenditure by substitution affordable generics with prescription drugs which are the fastest rising component of health care. Trend observed in US and Japan are increasing use of

Open Document